You may have exome or genome sequencing to investigate one problem and be offered analysis for certain unrelated health risks at the same time. Those additional results are called secondary findings. The decision is easier to understand when the diagnostic question and the additional analysis are explained separately.

This guide describes the ACMG approach to secondary findings in clinical exome and genome sequencing. The actual options depend on the laboratory, service and setting. Ask what is being offered rather than assuming every genetic test follows the same policy.

Illustrated overview of consent for additional findings, highlighting primary question, additional analysis, informed preferences.
Consent for additional findings: primary question, additional analysis, informed preferences. Read the article for evidence and limitations. Original conceptual illustration.

Open full-size illustration (new tab)

What is being looked for?

A primary finding concerns the reason for testing. A secondary finding comes from deliberately examining selected additional genes for medically relevant results unrelated to that reason. An incidental finding is encountered unexpectedly rather than deliberately sought in that additional analysis.

The MedlinePlus introduction to secondary findings explains the basic idea. Its examples of earlier gene lists should be read in their historical context; the list and reporting rules have been revised.

Editorial illustration: A person opening a primary test-results folder with a separate smaller optional folder beside it, clinician offering a choice before opening the second folder.
Conceptual illustration accompanying this article. People and situations depicted are fictional; this is not a diagnostic image.

Open full-size illustration (new tab)

The gene list is only part of the policy

The ACMG SF v3.3 publication from 2025 specifies gene–condition and variant-reporting criteria. It is not a catalogue of every gene affecting health. Inclusion of a gene does not make every rare change in that gene an actionable result. Under this secondary-findings framework, variants of uncertain significance are not reported as secondary findings.

Record which version the laboratory used. A newer publication does not mean that old samples have automatically been reassessed. Also ask whether the service offers a standard ACMG analysis or a different, explicitly described additional-results package.

Example 1: a useful additional result can leave the original question open

Fictional teaching example. An adult has genome sequencing to investigate an unexplained neurological problem. The diagnostic analysis remains inconclusive, but the agreed secondary analysis identifies a reportable finding associated with a cardiovascular condition.

There are now two separate conversations. The first concerns the unresolved neurological investigation. The second concerns what the additional finding means and what assessment is appropriate. It would be misleading to present the secondary result as the explanation for the original symptoms without evidence linking them.

A practical note for the appointment is: “My original question is still unresolved. The additional result needs its own explanation and follow-up plan.” Ask the clinician to state both parts clearly in the correspondence.

What consent should help you decide

The ACMG 2021 policy update supports an informed opportunity to opt out at consent. It also addresses disclosure in children and emphasizes their best interests. These recommendations should be discussed through the laboratory’s actual consent process, including how choices are documented.

Some people want potentially useful preventive information immediately; others want more time to consider additional results. A conversation should make room for either response. Ask for an explanation of the possible outcomes and the available choices before signing.

TopicAsk the service
ScopeWhich additional genes, conditions and variant types will you assess?
ChoiceHow do I accept or decline this analysis, and when can I change that decision?
ReportingWhich kinds of result will be returned, and which will not?
Follow-upWho will explain a finding and arrange the next assessment?
Family samplesAre relatives’ samples used only for comparison, or are they offered their own additional analysis?
Future contactWho is responsible for reassessment or contact if relevant knowledge changes?
Questions to settle before the sample is analyzed

Example 2: declining analysis and a negative result are different

Fictional teaching example. Two people say that their reports contain “no additional findings.” One declined the secondary analysis. The other accepted it, and no reportable result was found under the stated laboratory policy.

The first statement tells you about the scope of testing. The second tells you the outcome of an analysis with defined limits. Neither is a comprehensive guarantee of future health. The distinction matters when another clinician reads the report years later.

A clear record should state whether secondary analysis was performed and, if so, under which policy. Our guide to what a genetic test can miss explains why a negative result always needs its testing context.

Example 3: a VUS in the diagnostic search is a different kind of result

Fictional teaching example. A report lists a variant of uncertain significance in a gene being investigated for the patient’s symptoms. A separate section states that no reportable secondary finding was identified.

Those statements can coexist. The uncertain variant belongs to the diagnostic investigation; it is not being returned as an actionable secondary finding. Ask which section of the report a result belongs to before interpreting its significance. Our ACMG/AMP guide explains how evidence supports a classification.

Make a follow-up plan before the result gets lost

A reportable secondary finding may identify susceptibility rather than prove that disease is already present. Its implications need assessment in the individual’s clinical context. The ACMG policy describes this distinction between disclosure and subsequent medical management; the result is a starting point for that evaluation, not a universal treatment instruction.

  1. Keep the original report. Record the gene, variant, classification, report date and laboratory contact.
  2. Ask for a plain-language explanation. What is known, what remains uncertain and why might this matter?
  3. Agree on the next clinical contact. Identify the professional or service responsible for follow-up.
  4. Discuss family communication. Ask what information relatives might need and how to share it appropriately.
  5. Document the plan. Include who will do what and how questions or updates should reach the team.

The genetics care directory provides links to professional directories. For questions about a reported probability, read absolute and relative risk.

Research participation requires its own conversation

A research study and a clinical testing service may have different arrangements for analysis and return of results. Research consent should explain whether individual findings may be returned and how samples or genomic data may be shared. NHGRI discusses these issues in its guidance on genomic research consent.

Ask whether a returned research result needs clinical confirmation and who would arrange it. Do not assume that agreeing to a research study provides an ongoing clinical interpretation service.

Take this short summary to the consent discussion

“I understand the main reason for my test. I would like to know what additional analysis you offer, which results you return, how I can express my preference, and who will help if something is found.”

That request gives the conversation a clear starting point. You should leave knowing both what information you may receive and what will happen next.